proposed that Met‐activated AMPK can downregulate the expression of programmed death ligand‐1 (PD‐L1) in cancer cells by inducing abnormal degradation, which subsequently increases CD8+ T cell activity.[11] Moreover, several clinical trials are ongoing to investigate the antitumor effect of Met combinations in cancer immunotherapy.[12]. Here, CD8A is linked to cancer.